Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 24093630)

1.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

2.

Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.

Gong X, Schwartz PH, Linskey ME, Bota DA.

Neurology. 2011 Mar 29;76(13):1126-34. doi: 10.1212/WNL.0b013e318212a89f. Epub 2011 Feb 23.

3.
4.

Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.

Labussiere M, Pinel S, Delfortrie S, Plenat F, Chastagner P.

Oncol Rep. 2008 Nov;20(5):1283-7.

PMID:
18949434
5.

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L.

Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.

6.

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.

Morgillo F, D'Aiuto E, Troiani T, Martinelli E, Cascone T, De Palma R, Orditura M, De Vita F, Ciardiello F.

Lung Cancer. 2011 Mar;71(3):283-90. doi: 10.1016/j.lungcan.2010.06.005.

PMID:
20619923
7.

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC.

Clin Cancer Res. 2011 Aug 15;17(16):5311-21. doi: 10.1158/1078-0432.CCR-11-0476. Epub 2011 Jun 30.

8.

Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.

Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.

J Nucl Med. 2012 Nov;53(11):1764-71. doi: 10.2967/jnumed.111.101295. Epub 2012 Oct 10.

10.

Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ.

Mol Cancer Ther. 2003 Sep;2(9):835-43.

11.

Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.

Zhang X, Li W, Wang C, Leng X, Lian S, Feng J, Li J, Wang H.

Mol Cell Biochem. 2014 Jan;385(1-2):265-75. doi: 10.1007/s11010-013-1835-z. Epub 2013 Oct 9.

12.

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.

Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R.

Oncotarget. 2014 Nov 15;5(21):10280-92.

13.

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2010 Jul 21;102(14):1069-82. doi: 10.1093/jnci/djq198. Epub 2010 May 26.

14.

Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C.

Mol Cancer Ther. 2008 Jul;7(7):1949-60. doi: 10.1158/1535-7163.MCT-07-2046.

15.

Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.

Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF.

Clin Cancer Res. 2013 Aug 15;19(16):4392-403. doi: 10.1158/1078-0432.CCR-12-1557. Epub 2013 Jun 26.

16.

The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ.

Mol Cancer Ther. 2004 Jan;3(1):59-70. Erratum in: Mol Cancer Ther. 2009 Feb;8(2):479.

17.

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.

Breast Cancer Res. 2012 Apr 26;14(2):R68.

19.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

20.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

PMID:
25316808
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk